


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Cenobamate is a medication used in the management of partial-onset seizures in adults. It works by modulating both sodium channels and GABA receptors in the brain, making it effective in reducing the frequency of seizures. The drug is known for its high bioavailability and is typically administered orally.
The treatment begins with a low dose, which is titrated gradually. Its safety profile includes potential risks such as QT interval shortening and somnolence, so careful monitoring is advised. It is not recommended for individuals with certain heart conditions, such as familial short QT syndrome.
This manual consolidates the key details regarding Cenobamate from the available documentation.
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. It is used to help reduce the frequency and severity of seizures in individuals suffering from epilepsy characterized by partial-onset seizures.
The recommended initial dosage is 12.5 mg once daily, which can be titrated upward to a maintenance dose of 200 mg once daily.
